357 related articles for article (PubMed ID: 24330813)
1. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients.
Petricevic B; Laengle J; Singer J; Sachet M; Fazekas J; Steger G; Bartsch R; Jensen-Jarolim E; Bergmann M
J Transl Med; 2013 Dec; 11():307. PubMed ID: 24330813
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
Miura D; Yoneyama K; Furuhata Y; Shimizu K
J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Laengle J; Kabiljo J; Hunter L; Homola J; Prodinger S; Egger G; Bergmann M
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940587
[TBL] [Abstract][Full Text] [Related]
4. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
[TBL] [Abstract][Full Text] [Related]
5. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
[TBL] [Abstract][Full Text] [Related]
6. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
9. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.
Karagiannis P; Singer J; Hunt J; Gan SK; Rudman SM; Mechtcheriakova D; Knittelfelder R; Daniels TR; Hobson PS; Beavil AJ; Spicer J; Nestle FO; Penichet ML; Gould HJ; Jensen-Jarolim E; Karagiannis SN
Cancer Immunol Immunother; 2009 Jun; 58(6):915-30. PubMed ID: 18941743
[TBL] [Abstract][Full Text] [Related]
11. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.
Tsao LC; Crosby EJ; Trotter TN; Agarwal P; Hwang BJ; Acharya C; Shuptrine CW; Wang T; Wei J; Yang X; Lei G; Liu CX; Rabiola CA; Chodosh LA; Muller WJ; Lyerly HK; Hartman ZC
JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31689243
[TBL] [Abstract][Full Text] [Related]
12. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
13. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer.
Muraro E; De Zorzi M; Miolo G; Lombardi D; Scalone S; Spazzapan S; Massarut S; Perin T; Dolcetti R; Steffan A; De Re V
Front Immunol; 2021; 12():791958. PubMed ID: 35095867
[TBL] [Abstract][Full Text] [Related]
14. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
[TBL] [Abstract][Full Text] [Related]
15. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
18. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
[TBL] [Abstract][Full Text] [Related]
19. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
20. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A; Signorino E; Evangelista A; Brusa D; Mistrangelo M; Polimeni MA; Spadi R; Donadio M; Ciuffreda L; Matera L
J Transl Med; 2008 May; 6():25. PubMed ID: 18485193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]